Empagliflozin is named as a drug or biological intervention in 11 clinical trials in our India, UK, USA, China and Ireland trial registers, 9 of which are recruiting. Lead sponsors include Boehringer Ingelheim (5), Hoffmann-La Roche (1) and Colorado Prevention Center (1). Registered phases: Phase 3, Phase 4, Phase 1/2 and Not applicable. Conditions studied include Heart Failure; Diabetes Mellitus, Type 2; Hypertension.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Heart Failure | 3 |
| Diabetes Mellitus, Type 2 | 1 |
| Hypertension | 1 |
| Cardiovascular Diseases | 1 |
| Kidney Disease, Chronic | 1 |
| Metastatic Breast Cancer | 1 |
| Chronic Kidney Disease | 1 |
| Pneumonia | 1 |
| Kidney Transplant; Complications | 1 |
| Diabetes Mellitus | 1 |
| Cirrhotic Cardiomyopathy | 1 |
| Empagliflozin | 1 |
| Cardiometabolic Risk Factors | 1 |
| Cirrhosis | 1 |
| Type 2 Diabetic Kidney Disease | 1 |
| Lead sponsor | Trials |
|---|---|
| Boehringer Ingelheim | 5 |
| Hoffmann-La Roche | 1 |
| Colorado Prevention Center | 1 |
| University of Oxford | 1 |
| Medanta, The Medicity, India | 1 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | 1 |
| Huijie Zhang | 1 |
| Register | Empagliflozin trials |
|---|---|
| Clinical trials in India | 8 |
| Clinical trials in UK | 6 |
| Clinical trials in USA | 6 |
| Clinical trials in China | 6 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Empagliflozin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Empagliflozin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.